A historic milestone was set on June 28, 2023, when the U.S. Food and Drug Administration (FDA) granted approval for Lantidra to CellTrans, Inc., a company headquartered in Chicago, Illinois. Lantidra is a groundbreaking allogeneic pancreatic islet cellular therapy derived from the pancreatic cells of deceased donors. This landmark decision made it the world’s first cellular therapeutic to be approved for the treatment of type 1 diabetes, a disease that does not yet have a permanent treatment option. Lantridra is designed specifically for adults who have difficulty achieving target glycated hemoglobin levels due to recurring episodes of severe hypoglycemia. [Read more…]
iPSC-Derived NK Cells and the Future of Immunotherapy
By Richard Boyd PhDÂ and Alan Trounson PhD
Natural Killer (NK) cell therapies are rapidly emerging as a transformative force in healthcare, with promising potential across a range of conditions. They feature the complex killing capacity of classic immune system T cells but lack the prolonged time required for them to respond. With the armoury to rapidly detect and remove damaged, infected, senescent and cancerous cells throughout the body, they are nature’s frontline cell-mediated attack force. [Read more…]
Incucyte® CX3 System transforms continuous analysis of 3D cell models with confocal imaging and unmatched throughput
-
New confocal fluorescence imaging minimizes photobleaching and phototoxicity effects, capturing clear images of live 3D culture
-
Industry-leading throughput enables real-time analysis of up to six microplates in parallel, maximizing data generation
-
Comprehensive, intuitive workflows with integrated data analysis empower every scientist to generate high-quality data from complex assays with greater speed and confidence
How CellPort Is Making Cell Culture Smarter – Interview with Patrick Dentinger, CEO of CellPort Software
In the dynamic world of cell therapy, where precision and reproducibility are paramount, one scientist’s frustration with cell unpredictability sparked an industry-changing innovation. After years at the bench wrestling with the inherent variability of cell culture, Patrick Dentinger recognized a deeper problem—labs weren’t equipped with the right tools to track, understand, and manage cellular drift. [Read more…]
Vita Therapeutics and I Peace announced a development program to generate iPS- derived differentiated cells for transplant therapy with an initial focus on FSHD (Facioscapulohumeral Muscular Dystrophy) using universal iPS cells
Palo Alto, CA, July 10, 2025 –Â Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has agreed with Vita Therapeutics (Vita) to jointly develop universal iPS cells that will be used for cell transplantation therapy.
GMP-grade iPS cells will be modified with proprietary, licensed gene editing technology to make a base platform hypoimmune line where Class I and II HLA genes that determine rejection have been depleted. These hypoimmune lines can be further customized in I Peace cGMP facilities. [Read more…]
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 64
- Next Page »